TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00125034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops
Study: NCT01003054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
Study: NCT03165994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy, total dose 5040cGy in 180cGy fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV infusion
Study: NCT02661971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU 2600 mg/m², d1
Study: NCT03165994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of tumor
Description: Surgical removal of the tumor will occur between weeks 10-17
Study: NCT04035395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-led Support Group
Description: The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Health Consult
Description: In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
Study: NCT03210844

Intervention type: PROCEDURE
Intervention: Surgical approaches of total hip arthroplasty
Description: Surgical approaches of total hip arthroplasty

Intervention type: PROCEDURE
Intervention: Surgical approaches of total hip arthroplasty
Description: Surgical approaches of total hip arthroplasty
Study: NCT04035395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management Consult
Description: Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: La Cocina Alegre/ The Happy Kitchen
Description: The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
Study: NCT02137668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: Oral Vancomycin is given to PSC or BA participants
Study: NCT03842137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
Study: NCT04035395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind, Exercise, Nutrition, Do it!
Description: MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
Study: NCT00431912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO866
Description: APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
Study: NCT00520923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Taken PO (by mouth) QAM (every morning) for up to 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
Study: NCT04691895

Intervention type: OTHER
Intervention: SARS-CoV2 infection
Description: Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
Study: NCT00112463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
Study: NCT03600467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEVI-D (Seviteronel in combination with dexamthasone)
Description: Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study.
Study: NCT00915694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02554032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary artery cannulation
Description: The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
Study: NCT02661971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU 2600 mg/m², d1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8mg/kg, d1
Study: NCT00717080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOL surgery
Description: IOL surgery using capsular tension ring (AURORING)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IOL surgery
Description: IOL surgery without CTR
Study: NCT04154345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy (exercising into pain)
Description: The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
Study: NCT04029597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
Study: NCT01136122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP Treatment
Description: Effective CPAP treatment for one month
Study: NCT02092935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMT19969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT02315625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg daily will continue until progression or unacceptable treatment-related toxicity
Study: NCT03303482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)
Description: The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
Study: NCT02414503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8IU intranasal oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24IU intranasal oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OptiNose Breath Powered Bi

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OptiNose Breath Powered Bi

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OptiNose Breath Powered Bi
Study: NCT00958490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking program
Description: 4 week physical activity walking program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking program
Description: 4 week physical activity walking program
Study: NCT04566445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005: Medium Dose
Description: The study will test two doses of GT005: Medium Dose and High Dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT005: High Dose
Description: The study will test two doses of GT005: Medium Dose and High Dose.
Study: NCT02653261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of saline
Study: NCT01066676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: 400mg powder for oral suspension, daily dose 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400mg, powder for oral suspension, daily dose 1600mg
Study: NCT04070976

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Description: All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
Study: NCT01935310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved.
Study: NCT03272984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SC group
Description: Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
Study: NCT00675207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine purite 0.15%
Description: A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 2%
Description: A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1%
Description: A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
Study: NCT00983398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Given IA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study: NCT04609475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification technique
Description: Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motor driven expanders' technique
Description: The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
Study: NCT02956811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: SGLT2 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01136239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetycysteine (600mg twice daily)
Description: N-acetycysteine (600mg twice daily) for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (600mg twice daily)
Study: NCT01917123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Citrulline malate
Description: L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
Study: NCT01851512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-R (Test-Reference drug)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-T (Reference-Test drug)
Study: NCT02183974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptest
Study: NCT01182961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training
Description: subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training 2
Description: subjects will walk on a treadmill under a progressive intensive gait protocol
Study: NCT06195228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib or anlotinib plus anti-PD-1 antibody
Description: For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
Study: NCT01182961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise group
Description: standard of care exercise group to improve strength and balance
Study: NCT02763358

Intervention type: DEVICE
Group type: OTHER
Intervention: Bite Counter
Description: This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
Study: NCT05711147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abutment removal
Description: 4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of definitive abutment
Description: Placement of the final prosthetic abutment at the moment of implantation
Study: NCT05049694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zirconia crowns
Description: esthetic crowns for capping permanent molars with caries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel crowns
Description: stainless steel crowns for capping permanent molars with caries
Study: NCT03590002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic ICU Medical Transfer Tool
Description: Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.